American Society of Hematology

Figure 1.

$Effect of ruxolitinib on laboratory parameters (to last follow-up) and fevers (during hospitalization) with time course of therapy administration in the treatment of relapsed/refractory secondary HLH. Patient 1 (A-B) and patient 2 (C-D). CRP, C-reactive protein; Tmax, maximum temperature.$

Effect of ruxolitinib on laboratory parameters (to last follow-up) and fevers (during hospitalization) with time course of therapy administration in the treatment of relapsed/refractory secondary HLH. Patient 1 (A-B) and patient 2 (C-D). CRP, C-reactive protein; Tmax, maximum temperature.

This Feature Is Available To Subscribers Only